Aztreonam–avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial
Most Cited Paper
in Antibiotic Resistance in Bacteria
18 Months Post-Publication
Class of 2026
“Aztreonam–avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial”
A research intelligence initiative by Pepkio
pri.pepkio.com/top-papers/antibiotic-resistance-in-bacteria/2026/
Topics
aztreonam-avibactam · meropenem · Gram-negative bacteria · Severe infections · REVISIT trial · phase 3 trial · open-label trial · multinational study · randomised trial · comparative effectiveness · Antimicrobial resistance · β-lactamase inhibitor · carbapenem comparator · combination therapy
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Antibiotic Resistance in Bacteria Papers, Class of 2026. https://pri.pepkio.com/top-papers/antibiotic-resistance-in-bacteria/2026. Accessed 2026-07-17. Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459